Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Nov 1;5(11):1597-1604.
doi: 10.1001/jamaoncol.2019.2809.

Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer

Dawei Chen  1   2 , Hari Menon  1 , Vivek Verma  3 , Steven N Seyedin  4 , Jaffer A Ajani  5 , Wayne L Hofstetter  6 , Quynh-Nhu Nguyen  1 , Joe Y Chang  1 , Daniel R Gomez  1 , Arya Amini  7 , Stephen G Swisher  8 , Mariela A Blum  5 , Ahmed I Younes  1 , Hampartsoum B Barsoumian  1 , Jeremy J Erasmus  9 , Jeffrey H Lee  10 , Manoop S Bhutani  10 , Kenneth R Hess  11 , Bruce D Minsky  1 , James W Welsh  1
Affiliations
Clinical Trial

Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer

Dawei Chen et al. JAMA Oncol. .

Erratum in

  • Data Errors in the Results.
    [No authors listed] [No authors listed] JAMA Oncol. 2021 Apr 1;7(4):638. doi: 10.1001/jamaoncol.2021.0005. JAMA Oncol. 2021. PMID: 33599717 Free PMC article. No abstract available.

Abstract

Importance: Effective treatment options for locally advanced esophageal cancer are limited, and rates of local recurrence after standard chemoradiotherapy remain high.

Objective: To evaluate toxic effects, local control, and overall survival rates after chemoradiotherapy with a simultaneous integrated boost of radiotherapy dose to the gross tumor and nodal disease for patients with unresectable locally advanced esophageal cancer.

Design, setting, and participants: A phase 1/2, single-arm trial was conducted in 46 patients from April 28, 2010, to April 9, 2015 (median follow-up, 52 months [range, 2-86 months]), at a tertiary academic cancer center. Outcomes of the study patients were compared with those of 97 similar patients treated at the same institution from January 10, 2010, to December 5, 2014, as part of the interim analysis. Statistical analysis was performed from December 15, 2018, to February 12, 2019.

Interventions: Chemoradiotherapy with a simultaneous integrated boost of radiotherapy dose (50.4 Gy to subclinical areas at risk and 63.0 Gy to the gross tumor and involved nodes, all given in 28 fractions) with concurrent docetaxel and capecitabine or fluorouracil.

Main outcomes and measures: Toxic effects, local (in-field) control, and overall survival rates.

Results: All 46 patients (11 women and 35 men; median age, 65.5 years [range, 37.3-84.4 years]) received per-protocol therapy, as intensity-modulated photon therapy (39 [85%]) or intensity-modulated proton therapy (7 [15%]); 11 patients (24%) ultimately underwent resection. No patients experienced grade 4 or 5 toxic effects; the 10 acute grade 3 toxic events were esophagitis (4), dysphagia (3), and anorexia (3) and the 3 late grade 3 toxic events were all esophageal strictures. The actuarial local recurrence rates were 22% (95% CI, 11%-35%) at 6 months, 30% (95% CI, 18%-44%) at 1 year, and 33% (95% CI, 20%-46%) at 2 years. Overall, 15 patients (33%) experienced local failure, at a median interval of 5 months (range, 1-24 months). The median overall survival time was 21.5 months (range, 2.3-86.4 months). Exploratory comparison with a 97-patient contemporaneous institutional cohort receiving standard-dose (non-simultaneous integrated boost) chemoradiotherapy showed superior local control (hazard ratio, 0.49; 95% CI, 0.26-0.92; P = .03) and overall survival (hazard ratio, 0.66; 95% CI, 0.47-0.94; P = .02) in the group that received chemoradiotherapy with a simultaneous integrated boost.

Conclusions and relevance: These findings suggest that chemoradiotherapy with a simultaneous integrated boost of radiotherapy dose for locally advanced esophageal cancer is well tolerated, with encouraging local control, and thus warrants further study.

Trial registration: ClinicalTrials.gov identifier: NCT01102088.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Welsh reported receiving research support from GlaxoSmithKline, Bristol-Meyers Squibb, Merck, Nanobiotix, Mavu Pharmaceuticals, and Checkmate Pharmaceuticals; serving on the scientific advisory board for RefleXion Medical, MolecularMatch, OncoResponse, CheckMate, Mavu Pharmaceuticals, and Alpine Immune Sciences; being cofounder of Healios Oncology, MolecularMatch, and OncoResponse; serving as an advisor to AstraZeneca, Merck, MolecularMatch, Incyte, Aileron, and Nanobiotix; and holding patents for MP470 (amuvatinib), MRX34 regulation of PDL1, and XRT technique to overcome immune resistance (MD Anderson Cancer Center has a trademark for RadScopal). No other disclosures were reported.

Figures

Figure 1.
Figure 1.. CONSORT Diagram of the Trial
Figure 2.
Figure 2.. Local Recurrence Rate of the Study Population
A, Local recurrence in all patients. B, Local recurrence by histologic findings. Survival at 12 months was 32% in patients with adenocarcinoma (n = 22) and 29% in patients with squamous cell carcinoma. C, Local recurrence by nodal status. Survival at 12 months was 29% in patients with negative lymph nodes (n = 14) and 32% in patients with positive lymph nodes (n = 31). D, Local recurrence by radiotherapy type. Survival at 12 months was 33% in patients who received intensity-modulated (photon) radiotherapy (n = 39) and 14% in patients who received intensity-modulated proton therapy. Death was used as a competing risk. SCC indicates squamous cell carcinoma.
Figure 3.
Figure 3.. Overall Survival of the Study Population
SCC indicates squamous cell carcinoma; SIB, simultaneous integrated boost.
See this image and copyright information in PMC

Comment in

References

    1. Shapiro J, van Lanschot JJB, Hulshof MCCM, et al. ; CROSS study group . Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090-1098. doi:10.1016/S1470-2045(15)00040-6 - DOI - PubMed
    1. Tepper J, Krasna MJ, Niedzwiecki D, et al. . Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26(7):1086-1092. doi:10.1200/JCO.2007.12.9593 - DOI - PMC - PubMed
    1. Welsh J, Settle SH, Amini A, et al. . Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer. 2012;118(10):2632-2640. doi:10.1002/cncr.26586 - DOI - PMC - PubMed
    1. Minsky BD, Pajak TF, Ginsberg RJ, et al. . INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20(5):1167-1174. doi:10.1200/JCO.2002.20.5.1167 - DOI - PubMed
    1. Brower JV, Chen S, Bassetti MF, et al. . Radiation dose escalation in esophageal cancer revisited: a contemporary analysis of the National Cancer Data Base, 2004 to 2012. Int J Radiat Oncol Biol Phys. 2016;96(5):985-993. doi:10.1016/j.ijrobp.2016.08.016 - DOI - PubMed

Publication types

MeSH terms

Associated data

LinkOut - more resources